Infectious Disease Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years

This Phase III trial is testing a new vaccine designed to protect against 11 types of human papillomavirus (HPV) in Chinese women aged 18 to 45. HPV is a common infection that can lead to cervical and other cancers. If this vaccine proves effective, it could offer broader protection against multiple HPV strains, potentially lowering the risk of developing HPV-related cancers for many women.

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

This completed Phase 3 study evaluated an HPV vaccine therapy in women living with both HIV and HPV infection. The goal was to see if the vaccine could reduce serious cervical cell changes that often lead to cancer. Results from over 500 women in several African countries are now available and may support new ways to prevent cervical cancer in this higher-risk group.

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

This Phase 3 trial tested an oral antiviral drug called AK0529 in infants hospitalized with respiratory syncytial virus (RSV) infections. RSV is a common respiratory virus that can cause severe illness in young children. This study, which included 180 infants in China, aimed to show whether AK0529 can safely reduce the severity and length of illness. Results are pending and could lead to new treatment options for infants with RSV.

BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak

This ongoing Phase 4 study is evaluating the ERVEBO vaccine in frontline workers during an outbreak of Bundibugyo virus disease, a type of Ebola virus illness, in the Democratic Republic of the Congo. By studying about 20,000 workers, researchers hope to understand if the vaccine reduces severe illness and death. The results could help protect healthcare and emergency workers during future outbreaks.

Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: "Proof of Concept" Study (CoviDetectionDog)-Covid-19

This recently completed study explored whether trained detection dogs can identify people infected with SARS-CoV-2 who do not show symptoms. Conducted in France with 160 participants, the study aimed to find a new, non-invasive way to screen for COVID-19 early and help reduce virus spread. Results are expected to clarify the potential of this innovative screening method.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.